Initiator Pharma
7.4
SEK
+3.5 %
INIT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+3.5%
+2.78%
-5.73%
-26%
-19.91%
-20.26%
-7.5%
+9.53%
+64.97%
www.initiatorpharma.com/en
Initiator Pharma is a biotechnology company. Today, the main focus is to develop drug candidates to be used in treatment of erectile dysfunction in men. The company currently has pharmaceuticals in clinical stage testing for patients that do not respond on PDE5i pharmaceuticals. Initiator Pharma was created as a spin-off from Saniona and is today based in Åbyhøj.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
INIT
Daily low / high price
7 / 7.45
SEK
Market cap
415.57M SEK
Turnover
375.72K SEK
Volume
51K
Financial calendar
Annual report
2025-02-28
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Linc AB | 18.0 % | 18.0 % |
| Adrigo Asset Management | 6.5 % | 6.5 % |
| Avanza Pension | 5.9 % | 5.9 % |
| Mac Clinical Research Finance LTD | 5.5 % | 5.5 % |
| Claus Elsborg Olesen | 2.4 % | 2.4 % |
| Dan Peters | 2.2 % | 2.2 % |
| Nordnet Pensionsförsäkring | 1.7 % | 1.7 % |
| Annika Espander Jansson | 1.7 % | 1.7 % |
| Mikael Thomsen | 1.5 % | 1.5 % |
| Mats Thorén | 1.4 % | 1.4 % |
ShowingAll content types
Redeye: Initiator Pharma Q3 - Continued efforts in business development
INITIATOR PHARMA: Q3 2024 REPORT
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools